

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number  
WO 01/77306 A2

(51) International Patent Classification<sup>7</sup>: C12N 9/00

M. [US/US]; 2225 Rosewood Drive, Wilmington, DE 19810 (US). HITZ, William, D. [US/US]; 404 Hillside Road, Wilmington, DE 19807 (US).

(21) International Application Number: PCT/US01/10478

(22) International Filing Date: 30 March 2001 (30.03.2001)

(74) Agent: RIZZO, Thomas, M.; E. I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/196,550 11 April 2000 (11.04.2000) US

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (for all designated States except US): E. I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

(72) Inventors; and  
(75) Inventors/Applicants (for US only): ALLEN, Stephen,

[Continued on next page]

(54) Title: PLANT RAFFINOSE SACCHARIDE BIOSYNTHETIC ENZYMES

SEQ ID NO:02 -----MPPNITTVVANVTTEQLPKARGGSGRAFTFL  
SEQ ID NO:04 SLISTKLNHFLFPQNQLFLSSYFPFQIMPPNITTVVANVTTEQLPKARGGSGRAFTFL  
SEQ ID NO:05 A---PGLTQ-----TTTVKSAVTITK-PSPPVHGDRAVYVTF  
1 60

\*\*\*\*\*  
SEQ ID NO:02 AGNGDYVKGVVGLAKGLAKAKSMYPLVAVLPDVPEQHREILKSQGCIVREIEPVYPPE  
SEQ ID NO:04 AGNGDYVKGVVGLAKGLAKAKSMYPLVAVLPDVPEQHREILKSQGCIVREIEPVYPPE  
SEQ ID NO:05 AGNGDYVKGVVGLAKGLAKVKSAYPLVAVLPDVPEHRRVLVEQGCIVREIEPVYPPE  
61 120

\*\*\*\*\*  
SEQ ID NO:02 QTOFAMAYYVINYSTLPIMDFVDYNNITLYLOGDLQFGLTINHLFDLPDNYFYAVMDCFC  
SEQ ID NO:04 QTOFAMAYYVINYSLRINEFVEYKTIYLDGDIQVFNIDHLDLPDNYFYAVMDCFC  
SEQ ID NO:05 QTOFAMAYYVINYSLRIMFVEYSKMLYLDGDIQVFNIDHLDLPDNYFYAVMDCFC  
121 180

\*\*\*\*\*  
SEQ ID NO:02 NTRNQTQFQIGYCCQCPDKVQWASH-FGSKPPLYFNAGMFVEYEPNLDYRDLLOTVLT  
SEQ ID NO:04 KTWSHTPQFQIGYCCQCPDKVQWPSH-FGSKPPLYFNAGMFVEYEPNLDYRDLLOTVLT  
SEQ ID NO:05 KTWSHTPQYKIGYCCQCPDKVQWPSH-FGSKPPLYFNAGMFVEYEPNLDYRDLLOTVLT  
181 240

\*\*\*\*\*  
SEQ ID NO:02 KPTSPAEQDFLNMFKDKYKPIPNMYNLVLAHLNRHPENVELDKVQVHYCAAGSKPWF  
SEQ ID NO:04 KPTSPAEQDFLNMFKDKYKPIPNMYNLVLAHLNRHPENVELDKVQVHYCAAGSKPWF  
SEQ ID NO:05 PPTPFAEQDFLNMFKDKYKPIPLVYNLVLAHLNRHPENVELDKVQVHYCAAGSKPWF  
241 300

\*\*\*\*\*  
SEQ ID NO:02 TGKEENNDRADIKMLVKKNWDIYEDETLDYNN-----NSVNVERTSALLDAGGFQ  
SEQ ID NO:04 TGKEENNDREDIKMLVKKNWDIYEDETLDYNN-----NSVNVERTSALLDAGGFQ  
SEQ ID NO:05 TGKEANHEREDIKMLVKKNWDIYEDDSDYKKSVDLVEESDVVNLKPFISALTEAGPVK  
301 360

\*\*\*\*\*  
SEQ ID NO:02 FVPAASAA  
SEQ ID NO:04 FVPAASAA  
SEQ ID NO:05 YVTAASAA  
361 368

(57) Abstract: This invention relates to an isolated nucleic acid fragment encoding a galactinol synthase. The invention also relates to the construction of a chimeric gene encoding all or a portion of the galactinol synthase, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the galactinol synthase in a transformed host cell.

WO 01/77306 A2



patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *without international search report and to be republished upon receipt of that report*

TITLE

## PLANT RAFFINOSE SACCHARIDE BIOSYNTHETIC ENZYMES

This app. No. 60/196550,  
; PLANT RAFFINOSE SACCHARIDE BIOSYNTHETIC ENZYMES  
filed April 11,

FIELD OF THE INVENTION

This invention is in the field of plant molecular biology. More specifically, this invention pertains to nucleic acid fragments encoding a raffinose saccharide biosynthetic enzyme in plants and seeds.

BACKGROUND OF THE INVENTION

Raffinose saccharides are a group of D-galactose-containing oligosaccharide derivatives of sucrose that are widely distributed in plants. Raffinose saccharides are characterized by the general formula:  $[O-\beta\text{-D-galactopyranosyl-(1}\rightarrow\text{6)}_n-\alpha\text{-glucopyranosyl-(1}\rightarrow\text{2)}-\beta\text{-D-fructofuranoside}]$  where  $n=0$  through  $n=4$  are known respectively as sucrose, raffinose, stachyose, verbascose, and ajugose.

Extensive botanical surveys of the occurrence of raffinose saccharides have been reported in the scientific literature [see Dey (1985) in Biochemistry of Storage Carbohydrates in Green Plants, P. M. Dey and R. A. Dixon, Eds. Academic Press, London, pp. 53-129]. Raffinose saccharides are thought to be second only to sucrose with respect to abundance among the nonstructural carbohydrates in the plant kingdom. In fact, raffinose saccharides may be ubiquitous, at least among higher plants. Raffinose saccharides accumulate in significant quantities in the edible portion of many economically-significant crop species. Examples include soybean (*Glycine max* L. Merrill), sugar beet (*Beta vulgaris*), cotton (*Gossypium hirsutum* L.), canola (*Brassica sp.*) and all of the major edible leguminous crops including beans (*Phaseolus sp.*), chick pea (*Cicer arietinum*), cowpea (*Vigna unguiculata*), mung bean (*Vigna radiata*), peas (*Pisum sativum*), lentil (*Lens culinaris*) and lupine (*Lupinus sp.*).

Although abundant in many species, raffinose saccharides are an obstacle to the efficient utilization of some economically-important crop species. Raffinose saccharides are not digested directly by animals, primarily because alpha-galactosidase is not present in the intestinal mucosa [Gitzelmann et al. (1965) *Pediatrics* 36:231-236; Rutloff et al. (1967) *Nahrung* 11:39-46]. However, microflora in the lower gut are readily able to ferment the raffinose saccharides resulting in an acidification of the gut and production of carbon dioxide, methane and hydrogen gases [Murphy et al. (1972) *J. Agr. Food. Chem.* 20:813-817; Cristofaro et al. (1974) in Sugars in Nutrition, H. L. Sipple and K. W. McNutt, Eds. Academic Press, New York, Chap. 20, 313-335; Reddy et al. (1980) *J. Food Science* 45:1161-1164]. The resulting flatulence can severely limit the use of leguminous plants in animal, particularly human, diets. It is unfortunate that the presence of raffinose saccharides

restricts the use of legumes in human diets because many of these species are otherwise excellent sources of protein and soluble fiber. Varieties of edible beans free of raffinose saccharides would be more valuable for human diets and would more fully use the desirable nutritional qualities of edible leguminous plants.

5           The biosynthesis of raffinose saccharides has been well characterized [see Dey (1985) in *Biochemistry of Storage Carbohydrates in Green Plants*, P. M. Dey and R. A. Dixon, Eds. Academic Press, London, pp. 53-129]. The committed reaction of raffinose saccharide biosynthesis involves the synthesis of galactinol from UDP-galactose and myo-inositol. The enzyme that catalyzes this reaction is galactinol synthase (inositol 1-alpha-galactosyltransferase; EC 2.4.1.123). Synthesis of raffinose and higher homologues in the  
10 raffinose saccharide family from sucrose is thought to be catalyzed by distinct galactosyltransferases (for example, raffinose synthase and stachyose synthase). Studies in many species suggest that galactinol synthase is the key enzyme controlling the flux of reduced carbon into the biosynthesis of raffinose saccharides [Handley et al. (1983) *J. Amer. Soc. Hort. Sci.* 108:600-605; Saravitz, et al. (1987) *Plant Physiol.* 83:185-189]. Altering the  
15 activity of galactinol synthase, either as a result of overexpression or through antisense inhibition, would change the amount of raffinose saccharides produced in a given tissue.

Related galactinol synthase genes already known in the art include sequences disclosed in PCT/US92/06057 and U.S. 5,648,210, Kerr et al., "Nucleotide Sequences of  
20 Galactinol Synthase from Zucchini and Soybean" and Sprenger and Keller (2000) *Plant J* 21:249-258. Presumably related sequences are also disclosed in WO 98/50553, Lightner, "Corn Glycogenin".

There is a great deal of interest in identifying the genes that encode proteins involved in raffinose saccharides in plants. Specifically, the galactinol synthase gene may be used to  
25 alter galactinol synthesis and modulate the level of raffinose saccharides in plant cells. Accordingly, the availability of nucleic acid sequences encoding all or a portion of a galactinol synthase would facilitate studies to better understand raffinose synthesis in plants, and provide genetic tools to alter raffinose saccharide synthesis to enhance the nutritional  
30 qualities of many edible leguminous plants.

#### SUMMARY OF THE INVENTION

30           In a first embodiment, the present invention concerns an isolated polynucleotide comprising: (a) a nucleotide sequence encoding a polypeptide comprising at least 50 or 100 amino acids, wherein the amino acid sequence of the polypeptide and the amino acid  
35 sequence of SEQ ID NO:2 or SEQ ID NO:4 have at least 80%, 85%, 90%, or 95% identity based on the Clustal alignment method, or (b) the complement of the nucleotide sequence, wherein the complement and the nucleotide sequence contain the same number of nucleotides and are 100% complementary. The polypeptide preferably comprises the amino

acid sequence of SEQ ID NO:2 or SEQ ID NO:4. The nucleotide sequence preferably comprises the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3. The polypeptide preferably is a galactinol synthase.

5 In a second embodiment, the present invention relates to a chimeric gene comprising any of the isolated polynucleotides of the present invention operably linked to a regulatory sequence, and a cell, a plant, and a seed comprising the chimeric gene.

In a third embodiment, the present invention relates to a vector comprising any of the isolated polynucleotides of the present invention.

10 In a fourth embodiment, the present invention relates to an isolated polynucleotide comprising a nucleotide sequence comprised by any of the polynucleotides of the first embodiment, wherein the nucleotide sequence contains at least 30, 40, or 60 nucleotides, and a cell, a plant, and a seed comprising the isolated polynucleotide.

15 In a fifth embodiment, the present invention relates to a method for transforming a cell comprising transforming a cell with any of the isolated polynucleotides of the present invention, and the cell transformed by this method. Advantageously, the cell is eukaryotic, e.g., a yeast or plant cell, or prokaryotic, e.g., a bacterium.

20 In a sixth embodiment, the present invention relates to a method for producing a transgenic plant comprising transforming a plant cell with any of the isolated polynucleotides of the present invention and regenerating a plant from the transformed plant cell, the transgenic plant produced by this method, and the seed obtained from this transgenic plant.

25 In a seventh embodiment, the present invention concerns an isolated polypeptide comprising an amino acid sequence comprising at least 50 or 100 amino acids, wherein the amino acid sequence and the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 have at least 80%, 85%, 90%, or 95% identity based on the Clustal alignment method. The amino acid sequence preferably comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4. The polypeptide preferably is a galactinol synthase.

30 In an eighth embodiment, the present invention relates to a virus, preferably a baculovirus, comprising any of the isolated polynucleotides of the present invention or any of the chimeric genes of the present invention.

35 In a ninth embodiment, the invention relates to a method of selecting an isolated polynucleotide that affects the level of expression of a galactinol synthase protein or enzyme activity in a host cell, preferably a plant cell, the method comprising the steps of: (a) constructing an isolated polynucleotide of the present invention or an isolated chimeric gene of the present invention; (b) introducing the isolated polynucleotide or the isolated chimeric gene into a host cell; (c) measuring the level of the galactinol synthase protein or enzyme activity in the host cell containing the isolated polynucleotide; and (d) comparing

the level of the galactinol synthase protein or enzyme activity in the host cell containing the isolated polynucleotide with the level of the galactinol synthase protein or enzyme activity in the host cell that does not contain the isolated polynucleotide.

5 In a tenth embodiment, the invention concerns a method of obtaining a nucleic acid fragment encoding a substantial portion of a galactinol synthase protein, preferably a plant galactinol synthase protein, comprising the steps of: synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1 and 3, and the complement of such  
10 nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a substantial portion of a galactinol synthase protein amino acid sequence.

15 In an eleventh embodiment, this invention relates to a method of obtaining a nucleic acid fragment encoding all or a substantial portion of the amino acid sequence encoding a galactinol synthase protein comprising the steps of: probing a cDNA or genomic library with an isolated polynucleotide of the present invention; identifying a DNA clone that hybridizes with an isolated polynucleotide of the present invention; isolating the identified DNA clone; and sequencing the cDNA or genomic fragment that comprises the isolated  
20 DNA clone.

In a twelfth embodiment, this invention concerns a method for positive selection of a transformed cell comprising: (a) transforming a host cell with the chimeric gene of the present invention or an expression cassette of the present invention; and (b) growing the transformed host cell, preferably a plant cell, such as a monocot or a dicot, under conditions  
25 which allow expression of the galactinol synthase polynucleotide in an amount sufficient to complement a null mutant to provide a positive selection means.

In a thirteenth embodiment, this invention relates to a method of altering the level of expression of a galactinol synthase protein in a host cell comprising: (a) transforming a host cell with a chimeric gene of the present invention; and (b) growing the transformed host cell  
30 under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in production of altered levels of the galactinol synthase protein in the transformed host cell.

#### BRIEF DESCRIPTION OF THE DRAWING AND SEQUENCE LISTINGS

35 The invention can be more fully understood from the following detailed description and the accompanying drawing and Sequence Listing which form a part of this application.

Figure 1 depicts the amino acid sequence alignment between the galactinol synthase encoded by the nucleotide sequences derived from soybean clone ses4d.pk0017.b8 (SEQ ID NO:2 and SEQ ID NO:4) and the galactinol synthase from *Brassica napus* (NCBI GenBank Identifier (GI) No. 4588376; SEQ ID NO:5). Amino acids which are conserved among all and at least two sequences with an amino acid at that position are indicated with an asterisk (\*). Dashes are used by the program to maximize alignment of the sequences.

Table 1 lists the polypeptides that are described herein, the designation of the cDNA clones that comprise the nucleic acid fragments encoding polypeptides representing all or a substantial portion of these polypeptides, and the corresponding identifier (SEQ ID NO:) as used in the attached Sequence Listing. Table 1 also identifies the cDNA clones as individual ESTs ("EST"), the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), contigs assembled from two or more ESTs ("Contig"), contigs assembled from an FIS and one or more ESTs or PCR fragment sequence ("Contig\*"), or sequences encoding the entire protein derived from an EST, an FIS, a contig, or an FIS and PCR fragment sequence ("CGS"). SEQ ID NOs:1 and 2 presented herein correspond to SEQ ID NOs:1 and 2, respectively, presented in U.S. Provisional Application No. 60/196550, filed April 11, 2000. The sequence descriptions and Sequence Listing attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825.

TABLE 1

Raffinose Saccharide Biosynthetic Enzyme

Protein (Source)	Clone Designation	Status	SEQ ID NO:	
			(Nucleotide)	(Amino Acid)
Galactinol Synthase (Soybean)	ses4d.pk0017.b8 (FIS)	CGS	1	2
Galactinol Synthase (Soybean)	ses4d.pk0017.b8 (FIS)	CGS	3	4

The Sequence Listing contains the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IUBMB standards described in *Nucleic Acids Res.* 13:3021-3030 (1985) and in the *Biochemical J.* 219 (No. 2):345-373 (1984) which are herein incorporated by reference. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

DETAILED DESCRIPTION OF THE INVENTION

In the context of this disclosure, a number of terms shall be utilized. The terms "polynucleotide", "polynucleotide sequence", "nucleic acid sequence", and "nucleic acid fragment"/"isolated nucleic acid fragment" are used interchangeably herein. These terms

encompass nucleotide sequences and the like. A polynucleotide may be a polymer of RNA or DNA that is single- or double-stranded, that optionally contains synthetic, non-natural or altered nucleotide bases. A polynucleotide in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA, synthetic DNA, or mixtures thereof. An isolated polynucleotide of the present invention may include at least 5 60 contiguous nucleotides, preferably at least 40 contiguous nucleotides, most preferably at least 30 contiguous nucleotides derived from SEQ ID NOs:1 or 3, or the complement of such sequences.

The term "isolated" polynucleotide refers to a polynucleotide that is substantially 10 free from other nucleic acid sequences, such as and not limited to other chromosomal and extrachromosomal DNA and RNA. Isolated polynucleotides may be purified from a host cell in which they naturally occur. Conventional nucleic acid purification methods known to skilled artisans may be used to obtain isolated polynucleotides. The term also embraces recombinant polynucleotides and chemically synthesized polynucleotides.

15 The term "recombinant" means, for example, that a nucleic acid sequence is made by an artificial combination of two otherwise separated segments of sequence, e.g., by chemical synthesis or by the manipulation of isolated nucleic acids by genetic engineering techniques.

As used herein, "contig" refers to a nucleotide sequence that is assembled from two or more constituent nucleotide sequences that share common or overlapping regions of 20 sequence homology. For example, the nucleotide sequences of two or more nucleic acid fragments can be compared and aligned in order to identify common or overlapping sequences. Where common or overlapping sequences exist between two or more nucleic acid fragments, the sequences (and thus their corresponding nucleic acid fragments) can be assembled into a single contiguous nucleotide sequence.

25 As used herein, "substantially similar" refers to nucleic acid fragments wherein changes in one or more nucleotide bases results in substitution of one or more amino acids, but do not affect the functional properties of the polypeptide encoded by the nucleotide sequence. "Substantially similar" also refers to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect the ability of the nucleic acid fragment to 30 mediate alteration of gene expression by gene silencing through for example antisense or co-suppression technology. "Substantially similar" also refers to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially affect the functional properties of the resulting transcript vis-à-vis the ability to mediate gene silencing or alteration of the functional 35 properties of the resulting protein molecule. It is therefore understood that the invention encompasses more than the specific exemplary nucleotide or amino acid sequences and



includes functional equivalents thereof. The terms "substantially similar" and "corresponding substantially" are used interchangeably herein.

Substantially similar nucleic acid fragments may be selected by screening nucleic acid fragments representing subfragments or modifications of the nucleic acid fragments of the instant invention, wherein one or more nucleotides are substituted, deleted and/or inserted, for their ability to affect the level of the polypeptide encoded by the unmodified nucleic acid fragment in a plant or plant cell. For example, a substantially similar nucleic acid fragment representing at least 30 contiguous nucleotides derived from the instant nucleic acid fragment can be constructed and introduced into a plant or plant cell. The level of the polypeptide encoded by the unmodified nucleic acid fragment present in a plant or plant cell exposed to the substantially similar nucleic fragment can then be compared to the level of the polypeptide in a plant or plant cell that is not exposed to the substantially similar nucleic acid fragment.

For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than the entire coding region of a gene, and by using nucleic acid fragments that do not share 100% sequence identity with the gene to be suppressed. Moreover, alterations in a nucleic acid fragment which result in the production of a chemically equivalent amino acid at a given site, but do not effect the functional properties of the encoded polypeptide, are well known in the art. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the polypeptide molecule would also not be expected to alter the activity of the polypeptide. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Consequently, an isolated polynucleotide comprising a nucleotide sequence of at least 60 (preferably at least 40, most preferably at least 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1 and 3, and the complement of such nucleotide sequences may be used in methods of selecting an isolated polynucleotide that affects the expression of a galactinol synthase polypeptide in a host cell. A method of selecting an isolated polynucleotide that affects the level of expression of a polypeptide in a virus or in a host cell (eukaryotic, such as plant or yeast, prokaryotic such as bacterial) may comprise the steps of: constructing an isolated polynucleotide of the present invention or an isolated chimeric gene

of the present invention; introducing the isolated polynucleotide or the isolated chimeric gene into a host cell; measuring the level of a polypeptide or enzyme activity in the host cell containing the isolated polynucleotide; and comparing the level of a polypeptide or enzyme activity in the host cell containing the isolated polynucleotide with the level of a polypeptide or enzyme activity in a host cell that does not contain the isolated polynucleotide.

Moreover, substantially similar nucleic acid fragments may also be characterized by their ability to hybridize. Estimates of such homology are provided by either DNA-DNA or DNA-RNA hybridization under conditions of stringency as is well understood by those skilled in the art (Hames and Higgins, Eds. (1985) *Nucleic Acid Hybridisation*, IRL Press, Oxford, U.K.). Stringency conditions can be adjusted to screen for moderately similar fragments, such as homologous sequences from distantly related organisms, to highly similar fragments, such as genes that duplicate functional enzymes from closely related organisms. Post-hybridization washes determine stringency conditions. One set of preferred conditions uses a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2X SSC, 0.5% SDS at 45°C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 50°C for 30 min. A more preferred set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60°C. Another preferred set of highly stringent conditions uses two final washes in 0.1X SSC, 0.1% SDS at 65°C.

Substantially similar nucleic acid fragments of the instant invention may also be characterized by the percent identity of the amino acid sequences that they encode to the amino acid sequences disclosed herein, as determined by algorithms commonly employed by those skilled in this art. Suitable nucleic acid fragments (isolated polynucleotides of the present invention) encode polypeptides that are at least about 70% identical, preferably at least about 80% identical to the amino acid sequences reported herein. Preferred nucleic acid fragments encode amino acid sequences that are at least about 85% identical to the amino acid sequences reported herein. More preferred nucleic acid fragments encode amino acid sequences that are at least about 90% identical to the amino acid sequences reported herein. Most preferred are nucleic acid fragments that encode amino acid sequences that are at least about 95% identical to the amino acid sequences reported herein. Suitable nucleic acid fragments not only have the above identities but typically encode a polypeptide having at least 50 amino acids, preferably at least 100 amino acids, more preferably at least 150 amino acids, still more preferably at least 200 amino acids, and most preferably at least 250 amino acids. Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using

the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

5 A "substantial portion" of an amino acid or nucleotide sequence comprises an amino acid or a nucleotide sequence that is sufficient to afford putative identification of the protein or gene that the amino acid or nucleotide sequence comprises. Amino acid and nucleotide sequences can be evaluated either manually by one skilled in the art, or by using computer-based sequence comparison and identification tools that employ algorithms such as BLAST  
10 (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)). In general, a sequence of ten or more contiguous amino acids or thirty or more contiguous nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene-specific oligonucleotide probes  
15 comprising 30 or more contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12 or more nucleotides may be used as amplification primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers. Accordingly, a "substantial portion" of a  
20 nucleotide sequence comprises a nucleotide sequence that will afford specific identification and/or isolation of a nucleic acid fragment comprising the sequence. The instant specification teaches amino acid and nucleotide sequences encoding polypeptides that comprise one or more particular plant proteins. The skilled artisan, having the benefit of the sequences as reported herein, may now use all or a substantial portion of the disclosed  
25 sequences for purposes known to those skilled in this art. Accordingly, the instant invention comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.

"Codon degeneracy" refers to divergence in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded  
30 polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid sequences set forth herein. The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a nucleic acid fragment for improved expression in a host cell,  
35 it is desirable to design the nucleic acid fragment such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

"Synthetic nucleic acid fragments" can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form larger nucleic acid fragments which may then be enzymatically assembled to construct the entire desired nucleic acid fragment.

5 "Chemically synthesized", as related to a nucleic acid fragment, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of nucleic acid fragments may be accomplished using well established procedures, or automated chemical synthesis can be performed using one of a number of commercially available machines. Accordingly, the nucleic acid fragments can be tailored for optimal gene expression based on optimization  
10 of the nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.

"Gene" refers to a nucleic acid fragment that expresses a specific protein, including  
15 regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. "Native gene" refers to a gene as found in nature with its own regulatory sequences. "Chimeric gene" refers any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that  
20 are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. "Endogenous gene" refers to a native gene in its natural location in the genome of an organism. A "foreign-gene" refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise  
25 native genes inserted into a non-native organism, or chimeric genes. A "transgene" is a gene that has been introduced into the genome by a transformation procedure.

"Coding sequence" refers to a nucleotide sequence that codes for a specific amino acid sequence. "Regulatory sequences" refer to nucleotide sequences located upstream  
30 (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

"Promoter" refers to a nucleotide sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a  
35 promoter sequence. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an "enhancer" is a nucleotide sequence which can stimulate promoter activity and may be an innate element of

the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or may be composed of different elements derived from different promoters found in nature, or may even comprise synthetic nucleotide segments. It is understood by those skilled in the art that  
5 different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a nucleic acid fragment to be expressed in most cell types at most times are commonly referred to as "constitutive promoters". New promoters of various types useful in plant cells are constantly being discovered; numerous examples may be  
10 found in the compilation by Okamuro and Goldberg (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, nucleic acid fragments of different lengths may have identical promoter activity.

"Translation leader sequence" refers to a nucleotide sequence located between the  
15 promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner and Foster (1995) *Mol. Biotechnol.* 3:225-236).

"3' non-coding sequences" refer to nucleotide sequences located downstream of a  
20 coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is  
25 exemplified by Ingelbrecht et al. (1989) *Plant Cell* 1:671-680.

"RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from posttranscriptional processing of the primary transcript and is  
30 referred to as the mature RNA. "Messenger RNA (mRNA)" refers to the RNA that is without introns and that can be translated into polypeptides by the cell. "cDNA" refers to DNA that is complementary to and derived from an mRNA template. The cDNA can be single-stranded or converted to double stranded form using, for example, the Klenow fragment of DNA polymerase I. "Sense-RNA" refers to an RNA transcript that includes the  
35 mRNA and so can be translated into a polypeptide by the cell. "Antisense RNA" refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (see U.S. Patent No. 5,107,065,

incorporated herein by reference). The complementarity of an antisense RNA may be with any part of the specific nucleotide sequence, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. "Functional RNA" refers to sense RNA, antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular processes.

The term "operably linked" refers to the association of two or more nucleic acid fragments on a single polynucleotide so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

The term "expression", as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide.

"Antisense inhibition" refers to the production of antisense RNA transcripts capable of suppressing the expression of the target protein. "Overexpression" refers to the production of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms. "Co-suppression" refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. Patent No. 5,231,020, incorporated herein by reference).

A "protein" or "polypeptide" is a chain of amino acids arranged in a specific order determined by the coding sequence in a polynucleotide encoding the polypeptide. Each protein or polypeptide has a unique function.

"Altered levels" or "altered expression" refers to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms.

"Null mutant" refers here to a host cell which either lacks the expression of a certain polypeptide or expresses a polypeptide which is inactive or does not have any detectable expected enzymatic function.

"Mature protein" or the term "mature" when used in describing a protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. "Precursor protein" or the term "precursor" when used in describing a protein refers to the primary product of translation of mRNA; i.e., with pre- and propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

A "chloroplast transit peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the chloroplast or other plastid types

present in the cell in which the protein is made. "Chloroplast transit sequence" refers to a nucleotide sequence that encodes a chloroplast transit peptide. A "signal peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the secretory system (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53).

5 If the protein is to be directed to a vacuole, a vacuolar targeting signal (*supra*) can further be added, or if to the endoplasmic reticulum, an endoplasmic reticulum retention signal (*supra*) may be added. If the protein is to be directed to the nucleus, any signal peptide present should be removed and instead a nuclear localization signal included (Raikhel (1992) *Plant Phys.* 100:1627-1632).

10 "Transformation" refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" organisms. Examples of methods of plant transformation include *Agrobacterium*-mediated transformation (De Blaere et al. (1987) *Meth. Enzymol.* 143:277) and particle-accelerated or "gene gun" transformation technology (Klein et al. (1987) *Nature (London)* 327:70-73; U.S. Patent No. 4,945,050, incorporated herein by reference). Thus, isolated polynucleotides of the present invention can be incorporated into recombinant constructs, typically DNA constructs, capable of introduction into and replication in a host cell. Such a construct can be a vector that includes a replication system and sequences that are capable of transcription and translation of a

20 polypeptide-encoding sequence in a given host cell. A number of vectors suitable for stable transfection of plant cells or for the establishment of transgenic plants have been described in, e.g., Pouwels et al., *Cloning Vectors: A Laboratory Manual*, 1985, supp. 1987; Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academic Press, 1989; and Flevin et al., *Plant Molecular Biology Manual*, Kluwer Academic Publishers, 1990.

25 Typically, plant expression vectors include, for example, one or more cloned plant genes under the transcriptional control of 5' and 3' regulatory sequences and a dominant selectable marker. Such plant expression vectors also can contain a promoter regulatory region (e.g., a regulatory region controlling inducible or constitutive, environmentally- or developmentally-regulated, or cell- or tissue-specific expression), a transcription initiation start site, a

30 ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal.

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook et al. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989

35 (hereinafter "Maniatis").

"PCR" or "polymerase chain reaction" is well known by those skilled in the art as a technique used for the amplification of specific DNA segments (U.S. Patent Nos. 4,683,195 and 4,800,159).

5 The present invention concerns an isolated polynucleotide comprising: (a) a nucleotide sequence encoding a polypeptide comprising at least 50 or 100 amino acids, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 have at least 80%, 85%, 90%, or 95% identity based on the Clustal alignment method, or (b) the complement of the nucleotide sequence, wherein the complement and the nucleotide sequence contain the same number of nucleotides and are  
10 100% complementary. The polypeptide preferably comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4. The nucleotide sequence preferably comprises the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3. The polypeptide preferably is a galactinol synthase.

Nucleic acid fragments encoding at least a portion of several galactinol synthases  
15 have been isolated and identified by comparison of random plant cDNA sequences to public databases containing nucleotide and protein sequences using the BLAST algorithms well known to those skilled in the art. The nucleic acid fragments of the instant invention may be used to isolate cDNAs and genes encoding homologous proteins from the same or other plant species. Isolation of homologous genes using sequence-dependent protocols is well  
20 known in the art. Examples of sequence-dependent protocols include, but are not limited to, methods of nucleic acid hybridization, and methods of DNA and RNA amplification as exemplified by various uses of nucleic acid amplification technologies (e.g., polymerase chain reaction, ligase chain reaction).

For example, genes encoding other galactinol synthases, either as cDNAs or genomic  
25 DNAs, could be isolated directly by using all or a portion of the instant nucleic acid fragments as DNA hybridization probes to screen libraries from any desired plant employing methodology well known to those skilled in the art. Specific oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis). Moreover, an entire sequence can be used directly to synthesize DNA  
30 probes by methods known to the skilled artisan such as random primer DNA labeling, nick translation, end-labeling techniques, or RNA probes using available *in vitro* transcription systems. In addition, specific primers can be designed and used to amplify a part or all of the instant sequences. The resulting amplification products can be labeled directly during amplification reactions or labeled after amplification reactions, and used as probes to isolate  
35 full length cDNA or genomic fragments under conditions of appropriate stringency.

In addition, two short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols to amplify longer nucleic acid fragments encoding



homologous genes from DNA or RNA. The polymerase chain reaction may also be performed on a library of cloned nucleic acid fragments wherein the sequence of one primer is derived from the instant nucleic acid fragments, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3' end of the mRNA

5 precursor encoding plant genes. Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow the RACE protocol (Frohman et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:8998-9002) to generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3' or 5' end. Primers oriented in the 3' and 5' directions can be designed  
10 from the instant sequences. Using commercially available 3' RACE or 5' RACE systems (BRL), specific 3' or 5' cDNA fragments can be isolated (Ohara et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:5673-5677; Loh et al. (1989) *Science* 243:217-220). Products generated by the 3' and 5' RACE procedures can be combined to generate full-length cDNAs (Frohman and Martin (1989) *Techniques* 1:165). Consequently, a polynucleotide comprising a  
15 nucleotide sequence of at least 60 (preferably at least 40, most preferably at least 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1 and 3, and the complement of such nucleotide sequences may be used in such methods to obtain a nucleic acid fragment encoding a substantial portion of an amino acid sequence of a polypeptide.

20 The present invention relates to a method of obtaining a nucleic acid fragment encoding a substantial portion of a galactinol synthase polypeptide, preferably a substantial portion of a plant galactinol synthase polypeptide, comprising the steps of: synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least 60 (preferably at least 40, most preferably at least 30) contiguous nucleotides derived from a nucleotide sequence  
25 selected from the group consisting of SEQ ID NOs:1 and 3, and the complement of such nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a portion of a galactinol synthase polypeptide.

Availability of the instant nucleotide and deduced amino acid sequences facilitates  
30 immunological screening of cDNA expression libraries. Synthetic peptides representing portions of the instant amino acid sequences may be synthesized. These peptides can be used to immunize animals to produce polyclonal or monoclonal antibodies with specificity for peptides or proteins comprising the amino acid sequences. These antibodies can be then be used to screen cDNA expression libraries to isolate full-length cDNA clones of interest  
35 (Lerner (1984) *Adv. Immunol.* 36:1-34; Maniatis).

In another embodiment, this invention concerns viruses and host cells comprising either the chimeric genes of the invention as described herein or an isolated polynucleotide

of the invention as described herein. Examples of host cells which can be used to practice the invention include, but are not limited to, yeast, bacteria, and plants.

As was noted above, the nucleic acid fragments of the instant invention may be used to create transgenic plants in which the disclosed polypeptides are present at higher or lower levels than normal or in cell types or developmental stages in which they are not normally found. This would have the effect of altering the level of galactinol synthase, galactinol, and raffinose saccharides in those cells.

Overexpression of the proteins of the instant invention may be accomplished by first constructing a chimeric gene in which the coding region is operably linked to a promoter capable of directing expression of a gene in the desired tissues at the desired stage of development. The chimeric gene may comprise promoter sequences and translation leader sequences derived from the same genes. 3' Non-coding sequences encoding transcription termination signals may also be provided. The instant chimeric gene may also comprise one or more introns in order to facilitate gene expression.

Plasmid vectors comprising the instant isolated polynucleotide (or chimeric gene) may be constructed. The choice of plasmid vector is dependent upon the method that will be used to transform host plants. The skilled artisan is well aware of the genetic elements that must be present on the plasmid vector in order to successfully transform, select and propagate host cells containing the chimeric gene. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al. (1985) *EMBO J.* 4:2411-2418; De Almeida et al. (1989) *Mol. Gen. Genetics* 218:78-86), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

For some applications it may be useful to direct the instant polypeptides to different cellular compartments, or to facilitate its secretion from the cell. It is thus envisioned that the chimeric gene described above may be further supplemented by directing the coding sequence to encode the instant polypeptides with appropriate intracellular targeting sequences such as transit sequences (Keegstra (1989) *Cell* 56:247-253), signal sequences or sequences encoding endoplasmic reticulum localization (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53), or nuclear localization signals (Raikhel (1992) *Plant Phys.* 100:1627-1632) with or without removing targeting sequences that are already present. While the references cited give examples of each of these, the list is not exhaustive and more targeting signals of use may be discovered in the future.

It may also be desirable to reduce or eliminate expression of genes encoding the instant polypeptides in plants for some applications. In order to accomplish this, a chimeric

gene designed for co-suppression of the instant polypeptide can be constructed by linking a gene or gene fragment encoding that polypeptide to plant promoter sequences.

Alternatively, a chimeric gene designed to express antisense RNA for all or part of the instant nucleic acid fragment can be constructed by linking the gene or gene fragment in reverse orientation to plant promoter sequences. Either the co-suppression or antisense chimeric genes could be introduced into plants via transformation wherein expression of the corresponding endogenous genes are reduced or eliminated.

Molecular genetic solutions to the generation of plants with altered gene expression have a decided advantage over more traditional plant breeding approaches. Changes in plant phenotypes can be produced by specifically inhibiting expression of one or more genes by antisense inhibition or cosuppression (U.S. Patent Nos. 5,190,931, 5,107,065 and 5,283,323). An antisense or cosuppression construct would act as a dominant negative regulator of gene activity. While conventional mutations can yield negative regulation of gene activity these effects are most likely recessive. The dominant negative regulation available with a transgenic approach may be advantageous from a breeding perspective. In addition, the ability to restrict the expression of a specific phenotype to the reproductive tissues of the plant by the use of tissue specific promoters may confer agronomic advantages relative to conventional mutations which may have an effect in all tissues in which a mutant gene is ordinarily expressed.

The person skilled in the art will know that special considerations are associated with the use of antisense or cosuppression technologies in order to reduce expression of particular genes. For example, the proper level of expression of sense or antisense genes may require the use of different chimeric genes utilizing different regulatory elements known to the skilled artisan. Once transgenic plants are obtained by one of the methods described above, it will be necessary to screen individual transgenics for those that most effectively display the desired phenotype. Accordingly, the skilled artisan will develop methods for screening large numbers of transformants. The nature of these screens will generally be chosen on practical grounds. For example, one can screen by looking for changes in gene expression by using antibodies specific for the protein encoded by the gene being suppressed, or one could establish assays that specifically measure enzyme activity. A preferred method will be one which allows large numbers of samples to be processed rapidly, since it will be expected that a large number of transformants will be negative for the desired phenotype.

In another embodiment, the present invention concerns an isolated polypeptide comprising an amino acid sequence comprising at least 50 or 100 amino acids, wherein the amino acid sequence and the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 have at least 80%, 85%, 90%, or 95% identity based on the Clustal alignment method. The

amino acid sequence preferably comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4. The polypeptide preferably is a galactinol synthase.

The instant polypeptides (or portions thereof) may be produced in heterologous host cells, particularly in the cells of microbial hosts, and can be used to prepare antibodies to these proteins by methods well known to those skilled in the art. The antibodies are useful for detecting the polypeptides of the instant invention *in situ* in cells or *in vitro* in cell extracts. Preferred heterologous host cells for production of the instant polypeptides are microbial hosts. Microbial expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct a chimeric gene for production of the instant polypeptides. This chimeric gene could then be introduced into appropriate microorganisms via transformation to provide high level expression of the encoded galactinol synthase. An example of a vector for high level expression of the instant polypeptides in a bacterial host is provided (Example 6).

All or a substantial portion of the polynucleotides of the instant invention may also be used as probes for genetically and physically mapping the genes that they are a part of, and used as markers for traits linked to those genes. Such information may be useful in plant breeding in order to develop lines with desired phenotypes. For example, the instant nucleic acid fragments may be used as restriction fragment length polymorphism (RFLP) markers. Southern blots (Maniatis) of restriction-digested plant genomic DNA may be probed with the nucleic acid fragments of the instant invention. The resulting banding patterns may then be subjected to genetic analyses using computer programs such as MapMaker (Lander et al. (1987) *Genomics* 1:174-181) in order to construct a genetic map. In addition, the nucleic acid fragments of the instant invention may be used to probe Southern blots containing restriction endonuclease-treated genomic DNAs of a set of individuals representing parent and progeny of a defined genetic cross. Segregation of the DNA polymorphisms is noted and used to calculate the position of the instant nucleic acid sequence in the genetic map previously obtained using this population (Botstein et al. (1980) *Am. J. Hum. Genet.* 32:314-331).

The production and use of plant gene-derived probes for use in genetic mapping is described in Bernatzky and Tanksley (1986) *Plant Mol. Biol. Reporter* 4:37-41. Numerous publications describe genetic mapping of specific cDNA clones using the methodology outlined above or variations thereof. For example, F2 intercross populations, backcross populations, randomly mated populations, near isogenic lines, and other sets of individuals may be used for mapping. Such methodologies are well known to those skilled in the art.

Nucleic acid probes derived from the instant nucleic acid sequences may also be used for physical mapping (i.e., placement of sequences on physical maps; see Hoheisel et al. In:

*Nonmammalian Genomic Analysis: A Practical Guide*, Academic press 1996, pp. 319-346, and references cited therein).

In another embodiment, nucleic acid probes derived from the instant nucleic acid sequences may be used in direct fluorescence *in situ* hybridization (FISH) mapping (Trask  
5 (1991) *Trends Genet.* 7:149-154). Although current methods of FISH mapping favor use of large clones (several to several hundred KB; see Laan et al. (1995) *Genome Res.* 5:13-20), improvements in sensitivity may allow performance of FISH mapping using shorter probes.

A variety of nucleic acid amplification-based methods of genetic and physical mapping may be carried out using the instant nucleic acid sequences. Examples include  
10 allele-specific amplification (Kazazian (1989) *J. Lab. Clin. Med.* 11:95-96), polymorphism of PCR-amplified fragments (CAPS; Sheffield et al. (1993) *Genomics* 16:325-332), allele-specific ligation (Landegren et al. (1988) *Science* 241:1077-1080), nucleotide extension reactions (Sokolov (1990) *Nucleic Acid Res.* 18:3671), Radiation Hybrid Mapping (Walter et al. (1997) *Nat. Genet.* 7:22-28) and Happy Mapping (Dear and Cook (1989) *Nucleic Acid*  
15 *Res.* 17:6795-6807). For these methods, the sequence of a nucleic acid fragment is used to design and produce primer pairs for use in the amplification reaction or in primer extension reactions. The design of such primers is well known to those skilled in the art. In methods employing PCR-based genetic mapping, it may be necessary to identify DNA sequence differences between the parents of the mapping cross in the region corresponding to the  
20 instant nucleic acid sequence. This, however, is generally not necessary for mapping methods.

Loss of function mutant phenotypes may be identified for the instant cDNA clones either by targeted gene disruption protocols or by identifying specific mutants for these genes contained in a maize population carrying mutations in all possible genes (Ballinger  
25 and Benzer (1989) *Proc. Natl. Acad. Sci USA* 86:9402-9406; Koes et al. (1995) *Proc. Natl. Acad. Sci USA* 92:8149-8153; Bensen et al. (1995) *Plant Cell* 7:75-84). The latter approach may be accomplished in two ways. First, short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols in conjunction with a mutation tag sequence primer on DNAs prepared from a population of plants in which  
30 Mutator transposons or some other mutation-causing DNA element has been introduced (see Bensen, *supra*). The amplification of a specific DNA fragment with these primers indicates the insertion of the mutation tag element in or near the plant gene encoding the instant polypeptide. Alternatively, the instant nucleic acid fragment may be used as a hybridization probe against PCR amplification products generated from the mutation population using the mutation tag sequence primer in conjunction with an arbitrary genomic site primer, such as  
35 that for a restriction enzyme site-anchored synthetic adaptor. With either method, a plant containing a mutation in the endogenous gene encoding the instant polypeptide can be

identified and obtained. This mutant plant can then be used to determine or confirm the natural function of the instant polypeptides disclosed herein.

### EXAMPLES

The present invention is further defined in the following Examples, in which parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

The disclosure of each reference set forth herein is incorporated herein by reference in its entirety.

#### EXAMPLE 1

##### Composition of cDNA Libraries; Isolation and Sequencing of cDNA Clones

A cDNA library representing mRNAs from soybean (*Glycine max*) tissue was prepared. The characteristics of the library are described below.

TABLE 2

cDNA Libraries from Soybean

Library	Tissue	Clone
ses4d	Soybean Embryogenic Suspension 4 Days After Subculture	ses4d.pk0017.b8

cDNA libraries may be prepared by any one of many methods available. For example, the cDNAs may be introduced into plasmid vectors by first preparing the cDNA libraries in Uni-ZAP™ XR vectors according to the manufacturer's protocol (Stratagene Cloning Systems, La Jolla, CA). The Uni-ZAP™ XR libraries are converted into plasmid libraries according to the protocol provided by Stratagene. Upon conversion, cDNA inserts will be contained in the plasmid vector pBluescript. In addition, the cDNAs may be introduced directly into precut Bluescript II SK(+) vectors (Stratagene) using T4 DNA ligase (New England Biolabs), followed by transfection into DH10B cells according to the manufacturer's protocol (GIBCO BRL Products). Once the cDNA inserts are in plasmid vectors, plasmid DNAs are prepared from randomly picked bacterial colonies containing recombinant pBluescript plasmids, or the insert cDNA sequences are amplified via polymerase chain reaction using primers specific for vector sequences flanking the inserted cDNA sequences. Amplified insert DNAs or plasmid DNAs are sequenced in dye-primer

sequencing reactions to generate partial cDNA sequences (expressed sequence tags or "ESTs"; see Adams et al., (1991) *Science* 252:1651-1656). The resulting ESTs are analyzed using a Perkin Elmer Model 377 fluorescent sequencer.

Full-insert sequence (FIS) data is generated utilizing a modified transposition  
5 protocol. Clones identified for FIS are recovered from archived glycerol stocks as single colonies, and plasmid DNAs are isolated via alkaline lysis. Isolated DNA templates are reacted with vector primed M13 forward and reverse oligonucleotides in a PCR-based sequencing reaction and loaded onto automated sequencers. Confirmation of clone  
10 identification is performed by sequence alignment to the original EST sequence from which the FIS request is made.

Confirmed templates are transposed via the Primer Island transposition kit (PE Applied Biosystems, Foster City, CA) which is based upon the *Saccharomyces cerevisiae* Ty1 transposable element (Devine and Boeke (1994) *Nucleic Acids Res.* 22:3765-3772). The *in vitro* transposition system places unique binding sites randomly throughout a  
15 population of large DNA molecules. The transposed DNA is then used to transform DH10B electro-competent cells (Gibco BRL/Life Technologies, Rockville, MD) via electroporation. The transposable element contains an additional selectable marker (named DHFR; Fling and Richards (1983) *Nucleic Acids Res.* 11:5147-5158), allowing for dual selection on agar  
20 plates of only those subclones containing the integrated transposon. Multiple subclones are randomly selected from each transposition reaction, plasmid DNAs are prepared via alkaline lysis, and templates are sequenced (ABI Prism dye-terminator ReadyReaction mix) outward from the transposition event site, utilizing unique primers specific to the binding sites within the transposon.

Sequence data is collected (ABI Prism Collections) and assembled using Phred/Phrap  
25 (P. Green, University of Washington, Seattle). Phrep/Phrap is a public domain software program which re-reads the ABI sequence data, re-calls the bases, assigns quality values, and writes the base calls and quality values into editable output files. The Phrap sequence assembly program uses these quality values to increase the accuracy of the assembled sequence contigs. Assemblies are viewed by the Consed sequence editor (D. Gordon,  
30 University of Washington, Seattle).

In some of the clones the cDNA fragment corresponds to a portion of the 3'-terminus of the gene and does not cover the entire open reading frame. In order to obtain the upstream information one of two different protocols are used. The first of these methods results in the production of a fragment of DNA containing a portion of the desired gene  
35 sequence while the second method results in the production of a fragment containing the entire open reading frame. Both of these methods use two rounds of PCR amplification to obtain fragments from one or more libraries. The libraries some times are chosen based on

previous knowledge that the specific gene should be found in a certain tissue and some times are randomly-chosen. Reactions to obtain the same gene may be performed on several libraries in parallel or on a pool of libraries. Library pools are normally prepared using from 3 to 5 different libraries and normalized to a uniform dilution. . In the first round of  
5 amplification both methods use a vector-specific (forward) primer corresponding to a portion of the vector located at the 5'-terminus of the clone coupled with a gene-specific (reverse) primer. The first method uses a sequence that is complementary to a portion of the already known gene sequence while the second method uses a gene-specific primer complementary to a portion of the 3'-untranslated region (also referred to as UTR). In the second round of  
10 amplification a nested set of primers is used for both methods. The resulting DNA fragment is ligated into a pBluescript vector using a commercial kit and following the manufacturer's protocol. This kit is selected from many available from several vendors including Invitrogen (Carlsbad, CA), Promega Biotech (Madison, WI), and Gibco-BRL (Gaithersburg, MD). The plasmid DNA is isolated by alkaline lysis method and submitted for sequencing and  
15 assembly using Phred/Phrap, as above.

## EXAMPLE 2

### Identification of cDNA Clones

cDNA clones encoding galactinol synthase were identified by conducting BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see  
20 also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)) searches for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences obtained in Example 1 were analyzed for similarity to all publicly  
25 available DNA sequences contained in the "nr" database using the BLASTN algorithm provided by the National Center for Biotechnology Information (NCBI). The DNA sequences were translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish and States (1993) *Nat. Genet.* 3:266-272) provided by the NCBI. For convenience,  
30 the P-value (probability) of observing a match of a cDNA sequence to a sequence contained in the searched databases merely by chance as calculated by BLAST are reported herein as "pLog" values, which represent the negative of the logarithm of the reported P-value. Accordingly, the greater the pLog value, the greater the likelihood that the cDNA sequence and the BLAST "hit" represent homologous proteins.

35 ESTs submitted for analysis are compared to the genbank database as described above. ESTs that contain sequences more 5- or 3-prime can be found by using the BLASTn algorithm (Altschul et al (1997) *Nucleic Acids Res.* 25:3389-3402.) against the Du Pont



proprietary database comparing nucleotide sequences that share common or overlapping regions of sequence homology. Where common or overlapping sequences exist between two or more nucleic acid fragments, the sequences can be assembled into a single contiguous nucleotide sequence, thus extending the original fragment in either the 5 or 3 prime direction. Once the most 5-prime EST is identified, its complete sequence can be determined by Full Insert Sequencing as described in Example 1. Homologous genes belonging to different species can be found by comparing the amino acid sequence of a known gene (from either a proprietary source or a public database) against an EST database using the tBLASTn algorithm. The tBLASTn algorithm searches an amino acid query against a nucleotide database that is translated in all 6 reading frames. This search allows for differences in nucleotide codon usage between different species, and for codon degeneracy.

### EXAMPLE 3

#### Characterization of cDNA Clones Encoding Galactinol Synthase

The BLASTX search using the EST sequences from the clone listed in Table 3 revealed similarity of the polypeptides encoded by the cDNA to galactinol synthase from *Brassica napus* (NCBI GenBank Identifier (GI) No. 4588376). Shown in Table 3 are the BLAST results for individual ESTs ("EST"), the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), the sequences of contigs assembled from two or more ESTs ("Contig"), sequences of contigs assembled from an FIS and one or more ESTs ("Contig\*"), or sequences encoding an entire protein derived from an FIS, a contig, or an FIS and PCR ("CGS"):

TABLE 3

BLAST Results for Sequences Encoding Polypeptides Homologous to Galactinol Synthase

Clone	Status	BLAST pLog Score NCBI GI No. 4588376
ses4d.pk0017.b8 (FIS) (SEQ ID NO:1)	CGS	159.00
ses4d.pk0017.b8 (FIS) (SEQ ID NO:3)	CGS	149.00

SEQ ID NO:1 was previously presented in U.S. Provisional Application No. 60/196550, filed April 11, 2000. More sequence analysis and DNA sequencing of the insert in clone ses4d.pk0017.b8 yielded a more accurate nucleotide sequence of the cDNA insert which is presented in SEQ ID NO:3. Figure 1 presents an alignment of the amino acid sequences set forth in SEQ ID NOs:2 and 4 and the *Brassica napus* sequence (NCBI GI No. 4588376; SEQ ID NO:5). The data in Table 4 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOs:2 and 4 and the *Brassica napus* sequence (NCBI GI No. 4588376; SEQ ID NO:5).

TABLE 4

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences of cDNA Clones Encoding Polypeptides Homologous to Galactinol Synthase

SEQ ID NO.	Percent Identity to NCBI GI No. 4588376; SEQ ID NO:5
2	68.8
4	71.3

5        Sequence alignments and percent identity calculations were performed using the  
Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc.,  
Madison, WI). Multiple alignment of the sequences was performed using the Clustal  
method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default  
parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for  
10   pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3,  
WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and  
probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones  
encode a substantial portion of a galactinol synthase. These sequences represent new  
soybean sequences encoding galactinol synthase.

15

EXAMPLE 4Expression of Chimeric Genes in Monocot Cells

A chimeric gene comprising a cDNA encoding the instant polypeptide in sense  
orientation with respect to the maize 27 kD zein promoter that is located 5' to the cDNA  
fragment, and the 10 kD zein 3' end that is located 3' to the cDNA fragment, can be  
20   constructed. The cDNA fragment of this gene may be generated by polymerase chain  
reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites  
(NcoI or SmaI) can be incorporated into the oligonucleotides to provide proper orientation  
of the DNA fragment when inserted into the digested vector pML103 as described below.  
Amplification is then performed in a standard PCR. The amplified DNA is then digested  
25   with restriction enzymes NcoI and SmaI and fractionated on an agarose gel. The appropriate  
band can be isolated from the gel and combined with a 4.9 kb NcoI-SmaI fragment of the  
plasmid pML103. Plasmid pML103 has been deposited under the terms of the Budapest  
Treaty at ATCC (American Type Culture Collection, 10801 University Blvd., Manassas,  
VA 20110-2209), and bears accession number ATCC 97366. The DNA segment from  
30   pML103 contains a 1.05 kb Sall-NcoI promoter fragment of the maize 27 kD zein gene and  
a 0.96 kb SmaI-Sall fragment from the 3' end of the maize 10 kD zein gene in the vector  
pGem9Zf(+) (Promega). Vector and insert DNA can be ligated at 15°C overnight,  
essentially as described (Maniatis). The ligated DNA may then be used to transform *E. coli*  
XL1-Blue (Epicurian Coli XL-1 Blue™; Stratagene). Bacterial transformants can be

screened by restriction enzyme digestion of plasmid DNA and limited nucleotide sequence analysis using the dideoxy chain termination method (Sequenase™ DNA Sequencing Kit; U.S. Biochemical). The resulting plasmid construct would comprise a chimeric gene encoding, in the 5' to 3' direction, the maize 27 kD zein promoter, a cDNA fragment  
5 encoding the instant polypeptide, and the 10 kD zein 3' region.

The chimeric gene described above can then be introduced into corn cells by the following procedure. Immature corn embryos can be dissected from developing caryopses derived from crosses of the inbred corn lines H99 and LH132. The embryos are isolated 10 to 11 days after pollination when they are 1.0 to 1.5 mm long. The embryos are then placed  
10 with the axis-side facing down and in contact with agarose-solidified N6 medium (Chu et al. (1975) *Sci. Sin. Peking* 18:659-668). The embryos are kept in the dark at 27°C. Friable embryogenic callus consisting of undifferentiated masses of cells with somatic proembryoids and embryoids borne on suspensor structures proliferates from the scutellum of these immature embryos. The embryogenic callus isolated from the primary explant can  
15 be cultured on N6 medium and sub-cultured on this medium every 2 to 3 weeks.

The plasmid, p35S/Ac (obtained from Dr. Peter Eckes, Hoechst Ag, Frankfurt, Germany) may be used in transformation experiments in order to provide for a selectable marker. This plasmid contains the *Pat* gene (see European Patent Publication 0 242 236) which encodes phosphinothricin acetyl transferase (PAT). The enzyme PAT confers  
20 resistance to herbicidal glutamine synthetase inhibitors such as phosphinothricin. The *pat* gene in p35S/Ac is under the control of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*.

The particle bombardment method (Klein et al. (1987) *Nature* 327:70-73) may be  
25 used to transfer genes to the callus culture cells. According to this method, gold particles (1 µm in diameter) are coated with DNA using the following technique. Ten µg of plasmid DNAs are added to 50 µL of a suspension of gold particles (60 mg per mL). Calcium chloride (50 µL of a 2.5 M solution) and spermidine free base (20 µL of a 1.0 M solution) are added to the particles. The suspension is vortexed during the addition of these solutions.  
30 After 10 minutes, the tubes are briefly centrifuged (5 sec at 15,000 rpm) and the supernatant removed. The particles are resuspended in 200 µL of absolute ethanol, centrifuged again and the supernatant removed. The ethanol rinse is performed again and the particles resuspended in a final volume of 30 µL of ethanol. An aliquot (5 µL) of the DNA-coated gold particles can be placed in the center of a Kapton™ flying disc (Bio-Rad Labs). The  
35 particles are then accelerated into the corn tissue with a Biolistic™ PDS-1000/He (Bio-Rad Instruments, Hercules CA), using a helium pressure of 1000 psi, a gap distance of 0.5 cm and a flying distance of 1.0 cm.

For bombardment, the embryogenic tissue is placed on filter paper over agarose-solidified N6 medium. The tissue is arranged as a thin lawn and covered a circular area of about 5 cm in diameter. The petri dish containing the tissue can be placed in the chamber of the PDS-1000/He approximately 8 cm from the stopping screen. The air in the chamber is then evacuated to a vacuum of 28 inches of Hg. The macrocarrier is accelerated with a helium shock wave using a rupture membrane that bursts when the He pressure in the shock tube reaches 1000 psi.

Seven days after bombardment the tissue can be transferred to N6 medium that contains bialophos (5 mg per liter) and lacks casein or proline. The tissue continues to grow slowly on this medium. After an additional 2 weeks the tissue can be transferred to fresh N6 medium containing bialophos. After 6 weeks, areas of about 1 cm in diameter of actively growing callus can be identified on some of the plates containing the bialophos-supplemented medium. These calli may continue to grow when sub-cultured on the selective medium.

Plants can be regenerated from the transgenic callus by first transferring clusters of tissue to N6 medium supplemented with 0.2 mg per liter of 2,4-D. After two weeks the tissue can be transferred to regeneration medium (Fromm et al. (1990) *Bio/Technology* 8:833-839).

#### EXAMPLE 5

##### Expression of Chimeric Genes in Dicot Cells

A seed-specific expression cassette composed of the promoter and transcription terminator from the gene encoding the  $\beta$  subunit of the seed storage protein phaseolin from the bean *Phaseolus vulgaris* (Doyle et al. (1986) *J. Biol. Chem.* 261:9228-9238) can be used for expression of the instant polypeptides in transformed soybean. The phaseolin cassette includes about 500 nucleotides upstream (5') from the translation initiation codon and about 1650 nucleotides downstream (3') from the translation stop codon of phaseolin. Between the 5' and 3' regions are the unique restriction endonuclease sites Nco I (which includes the ATG translation initiation codon), Sma I, Kpn I and Xba I. The entire cassette is flanked by Hind III sites.

The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the expression vector. Amplification is then performed as described above, and the isolated fragment is inserted into a pUC18 vector carrying the seed expression cassette.

Soybean embryos may then be transformed with the expression vector comprising sequences encoding the instant polypeptides. To induce somatic embryos, cotyledons,

3-5 mm in length dissected from surface sterilized, immature seeds of the soybean cultivar A2872, can be cultured in the light or dark at 26°C on an appropriate agar medium for 6-10 weeks. Somatic embryos which produce secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic embryos which multiplied as early, globular staged embryos, the suspensions are maintained as described below.

Soybean embryogenic suspension cultures can be maintained in 35 mL liquid media on a rotary shaker, 150 rpm, at 26°C with florescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 mL of liquid medium.

Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Klein et al. (1987) *Nature* (London) 327:70-73, U.S. Patent No. 4,945,050). A DuPont Biolistic™ PDS1000/HE instrument (helium retrofit) can be used for these transformations.

A selectable marker gene which can be used to facilitate soybean transformation is a chimeric gene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from *E. coli*; Gritz et al. (1983) *Gene* 25:179-188) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*. The seed expression cassette comprising the phaseolin 5' region, the fragment encoding the instant polypeptide and the phaseolin 3' region can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.

To 50 µL of a 60 mg/mL 1 µm gold particle suspension is added (in order): 5 µL DNA (1 µg/µL), 20 µL spermidine (0.1 M), and 50 µL CaCl<sub>2</sub> (2.5 M). The particle preparation is then agitated for three minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles are then washed once in 400 µL 70% ethanol and resuspended in 40 µL of anhydrous ethanol. The DNA/particle suspension can be sonicated three times for one second each. Five µL of the DNA-coated gold particles are then loaded on each macro carrier disk.

Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette. For each transformation experiment, approximately 5-10 plates of tissue are normally bombarded. Membrane rupture pressure is set at 1100 psi and the chamber is evacuated to a vacuum of 28 inches mercury. The tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.

Five to seven days post bombardment, the liquid media may be exchanged with fresh media, and eleven to twelve days post bombardment with fresh media containing 50 mg/mL hygromycin. This selective media can be refreshed weekly. Seven to eight weeks post bombardment, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos.

#### EXAMPLE 6

##### Expression of Chimeric Genes in Microbial Cells

The cDNAs encoding the instant polypeptides can be inserted into the T7 *E. coli* expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) *Gene* 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in pET-3a at their original positions. An oligonucleotide adaptor containing EcoR I and Hind III sites was inserted at the BamH I site of pET-3a. This created pET-3aM with additional unique cloning sites for insertion of genes into the expression vector. Then, the Nde I site at the position of translation initiation was converted to an Nco I site using oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region, 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.

Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the protein. This fragment may then be purified on a 1% low melting agarose gel. Buffer and agarose contain 10 µg/ml ethidium bromide for visualization of the DNA fragment. The fragment can then be purified from the agarose gel by digestion with GELase™ (Epicentre Technologies, Madison, WI) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 µL of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase (New England Biolabs (NEB), Beverly, MA). The fragment containing the ligated adapters can be purified from the excess adapters using low melting agarose as described above. The vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can then be ligated at 16°C for 15 hours followed by transformation into DH5 electrocompetent cells (GIBCO BRL). Transformants can be selected on agar plates containing LB media and 100 µg/mL ampicillin. Transformants containing the gene encoding the instant polypeptide are then screened for the correct orientation with respect to the T7 promoter by restriction enzyme analysis.

For high level expression, a plasmid clone with the cDNA insert in the correct orientation relative to the T7 promoter can be transformed into *E. coli* strain BL21(DE3) (Studier et al. (1986) *J. Mol. Biol.* 189:113-130). Cultures are grown in LB medium containing ampicillin (100 mg/L) at 25°C. At an optical density at 600 nm of approximately 5 1, IPTG (isopropylthio- $\beta$ -galactoside, the inducer) can be added to a final concentration of 0.4 mM and incubation can be continued for 3 h at 25°. Cells are then harvested by centrifugation and re-suspended in 50  $\mu$ L of 50 mM Tris-HCl at pH 8.0 containing 0.1 mM DTT and 0.2 mM phenyl methylsulfonyl fluoride. A small amount of 1 mm glass beads can be added and the mixture sonicated 3 times for about 5 seconds each time with a microprobe 10 sonicator. The mixture is centrifuged and the protein concentration of the supernatant determined. One  $\mu$ g of protein from the soluble fraction of the culture can be separated by SDS-polyacrylamide gel electrophoresis. Gels can be observed for protein bands migrating at the expected molecular weight.

CLAIMS

What is claimed is:

1. An isolated polynucleotide comprising:
  - (a) a nucleotide sequence encoding a polypeptide having galactinol synthase activity, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 have at least 80% identity based on the Clustal alignment method, or
  - (b) the complement of the nucleotide sequence.
2. The isolated polynucleotide of Claim 1, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 have at least 85% identity based on the Clustal alignment method.
3. The isolated polynucleotide of Claim 1, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 have at least 90% identity based on the Clustal alignment method.
4. The isolated polynucleotide of Claim 1, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 have at least 95% identity based on the Clustal alignment method.
5. The isolated polynucleotide of Claim 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.
6. The isolated polynucleotide of Claim 1, wherein the nucleotide sequence comprises the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3.
7. An isolated polynucleotide comprising a nucleotide sequence containing at least 30 nucleotides, wherein the nucleotide sequence containing at least 30 nucleotides is comprised by the polynucleotide of Claim 1.
8. The polynucleotide of Claim 7, wherein the nucleotide sequence containing at least 30 nucleotides contains at least 40 nucleotides.
9. The polynucleotide of Claim 7, wherein the nucleotide sequence containing at least 30 nucleotides contains at least 60 nucleotides.
10. A chimeric gene comprising the polynucleotide of Claim 1 or Claim 7 operably linked to a regulatory sequence.
11. A vector comprising the polynucleotide of Claim 1 or Claim 7.
12. A method for transforming a cell comprising transforming a cell with the polynucleotide of Claim 1 or Claim 7.
13. A cell comprising the chimeric gene of Claim 10.
14. A method for producing a transgenic plant comprising transforming a plant cell with the polynucleotide of Claim 1 or Claim 7 and regenerating a plant from the transformed plant cell.



15. A plant comprising the chimeric gene of Claim 10.
16. A seed comprising the chimeric gene of Claim 10.
17. An isolated polypeptide having galactinol synthase activity, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 have at least 80% identity based on the Clustal alignment method.
18. The polypeptide of Claim 17, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 have at least 85% identity based on the Clustal alignment method.
19. The polypeptide of Claim 17, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 have at least 90% identity based on the Clustal alignment method.
20. The polypeptide of Claim 17, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 have at least 95% identity based on the Clustal alignment method.
21. The polypeptide of Claim 17, wherein the amino acid sequence of the polypeptide comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.

FIGURE 1

SEQ ID NO:02	*	****	***	**	**	**	****
SEQ ID NO:04	-----	MPPNITTVVANVTTEQLPKARGGSGRAFTVL					
SEQ ID NO:05	SLISTKLNHFLFPQNQLSSYFFQIMPPNITTVVANVTTEQLPKARGGSGRAFTVL						
	A---PGLTQ-----	TTTVKSAVTITK-PSPPVHGDRAVYVTEL					
	1						60
SEQ ID NO:02	*****	**	*****	**	*	*****	*****
SEQ ID NO:04	AGNGDYVKGVVGLAKGLRKA	KSMYPLVAVLPDVP	EQHREILKSQGCIVREIEPVYPPEN				
SEQ ID NO:05	AGNGDYVKGVVGLAKGLRKA	KSMYPLVAVLPDVP	EEHREILKSQGCIVREIEPVYPPEN				
	AGNGDYVKGVVGLAKGLRKA	KSAYPLVAILPDVP	EEHRRVLVEQGCIVREIEPVYPPEN				
	61						120
SEQ ID NO:02	*****	*	*****	*	*****	*****	*****
SEQ ID NO:04	QTQFAMAYYVINYSTLP	PIWDFVDYNN	TYLDGDLQLEGTINHLFDLP	DNYFYAVMDCFC			
SEQ ID NO:05	QTQFAMAYYVINYSKLRI	WEFVEYKKT	TYLDGDIQVFGNIDHLE	FDLPDNYFYAVMDCFCE			
	QTQFAMAYYVINYSKLRI	WKFEYSKMLYLDGDIQVYENIDHLE	FDLPDGYFYAVMDCFCE				
	121						180
SEQ ID NO:02	*	***	*****	***	*	*****	*
SEQ ID NO:04	NTRNQT	PQEQIGYCQCQCPDKVQWASH-FGSKPPLYFNAGMFVYEPNLD	TYRDL	LIQTVQLT			
SEQ ID NO:05	KTSHTP	QFQIGYCQCQCPDKVQWPSH-FGSKPPLYFNAGMFVYEPNLD	TYRDL	LIQTVQLT			
	KTSHTP	QYKIGYCQCQCPDKVQWPKDELGEPPSLYFNAGMFVFEPLD	TYEDLLRLTKIT				
	181						240
SEQ ID NO:02	**	*****	*****	*****	*****	*****	*****
SEQ ID NO:04	KPTSFAEQD	FLNMYFKDKYKPIPNMYNLVLAMLRHPENVELDKVQV	VHYCAAGSKPWRF				
SEQ ID NO:05	KPTSFAEQD	FLNMYFKDKYKPIPNMYNLVLAMLRHPENVELDKVQV	VHYCAAGSKPWRF				
	PPTPFAEQD	FLNMYFEKIYKPIPLVYNLVLAMLRHPENVELDKVQV	VHYCAAGSKPWRY				
	241						300

**FIGURE 1 CONTINUED**

\*\*\*\* \* \* \*\*\*\* \* \*\*\*\* \* \*  
 TGKEENMDRADIKMLVKKWDIYEDETLDYNN-----NSVNVERFTSALLDAGGFQ  
 TGKEENMDREDIKMLVKKWDIYEDETLDYNN-----NSVNVERFTSALLDAGGFQ  
 TGKEANMEREDIKMLVNKWDIYNDDSLDYKKSVDLVEESDVNLPFFISALTEAGPVR  
 301 360

SEQ	ID	NO:02
SEQ	ID	NO:04
SEQ	ID	NO:05

\* \* \* \* \*

FVPAPSAA  
FVPAPSAA  
YVTAPSAA  
361 368

SEQ	ID	NO: 02
SEQ	ID	NO: 04
SEQ	ID	NO: 05

SEQUENCE LISTING

&lt;110&gt; E.I. du Pont de Nemours and Company

&lt;120&gt; Plant Raffinose Biosynthetic Enzymes

&lt;130&gt; BB1442

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; 60/196550

&lt;151&gt; 2000-04-11

&lt;160&gt; 5

&lt;170&gt; Microsoft Office 97

&lt;210&gt; 1

&lt;211&gt; 1342

&lt;212&gt; DNA

&lt;213&gt; Glycine max

&lt;400&gt; 1

```

aaacaaccaa cctcttcagt gatctttgat tagtactaag ctaaaccatt tottattccc 60
tcaaaatcaa aacctttttc tttctagcta tttccctttt caaatcatgc cacctaacat 120
caccaccgtt gttgccaatg tcaccaccga gcaattacc aaggctcgtg gaggaagtgg 180
gcgtgccttc gtgacctttc ttgctgggaa cggtgattac gtaaagggtg tctgtgggtt 240
ggccaaagga ctgagaaagg ccaaaagcat gtacctttg gtggttgctg tgttaccaga 300
tgttcctgaa caacatcgtg agattctcaa atcccaagg tgcattgtca gggagattga 360
acctgtgtac cctcctgaga accagacca gttcgccatg gcctattatg tcatcaatta 420
ctccacgcta cctattttgg atttcgtgga ctacaacaac accatatacc tagacggtga 480
cctccaacta tttggaacca taaaccactt gtttgatctg cctgataatt atttctatgc 540
ggtgatggat tgtttctgcg acaacaccgg gaaccagacc cctcagttcc agattgggta 600
ctgccaacag tgccctgata aggttcaatg ggcctctcac tttggttcca aacctcctct 660
atatttcaat gctggcatgt ttgtttatga acctaatctc gacacctacc gtgatcttct 720
ccaaactgtc caactcacca agcccaacttc ttttgctgag caggactttc tcaacatgta 780
cttcaaggac aagtacaagc caataccgaa catgtacaac cttgtgctgg ccatgttgtg 840
gcgtcacctt gaaaatgttg aacttgataa agttcaagtg gttcattact gtgctgctgg 900
gtctaagcct tggaggttca ctgggaagga agagaacatg gatagggcag atatcaagat 960
gcttgatgaag aagtgggtggg acatatatga agatgagaca ctggactaca ataacaactc 1020
tgtcaacgtg gaacgtttca catcggcact attggatgct gggggctttc agtttggtcc 1080
agcaccttct gctgccta atgcttatta ttacagcta cacattaatg ttaattaacg 1140
acaaagtata tgtattgtta tttgcttttt ttcgtttttg ggtcttatat atgaaggaa 1200
aacgttttat gttttaattt ggatgacctt cttgtatata aagccacatg tgatctcata 1260
cagcttttga ttattattaa gaaattagag gaccttttat tatgagtcct ttacttaaaa 1320
aaaaaaaaac aaaaaaaaaa aa 1342

```

&lt;210&gt; 2

&lt;211&gt; 330

&lt;212&gt; PRT

&lt;213&gt; Glycine max

&lt;400&gt; 2

```

Met Pro Pro Asn Ile Thr Thr Val Val Ala Asn Val Thr Thr Glu Gln
  1              5              10              15
Leu Pro Lys Ala Arg Gly Gly Ser Gly Arg Ala Phe Val Thr Phe Leu
              20              25              30

```

Ala Gly Asn Gly Asp Tyr Val Lys Gly Val Val Gly Leu Ala Lys Gly  
                   35                                  40                                  45  
 Leu Arg Lys Ala Lys Ser Met Tyr Pro Leu Val Val Ala Val Leu Pro  
                   50                                  55                                  60  
 Asp Val Pro Glu Gln His Arg Glu Ile Leu Lys Ser Gln Gly Cys Ile  
                   65                                  70                                  75                                  80  
 Val Arg Glu Ile Glu Pro Val Tyr Pro Pro Glu Asn Gln Thr Gln Phe  
                                   85                                  90                                  95  
 Ala Met Ala Tyr Tyr Val Ile Asn Tyr Ser Thr Leu Pro Ile Trp Asp  
                                   100                                  105                                  110  
 Phe Val Asp Tyr Asn Asn Thr Ile Tyr Leu Asp Gly Asp Leu Gln Leu  
                   115                                  120                                  125  
 Phe Gly Thr Ile Asn His Leu Phe Asp Leu Pro Asp Asn Tyr Phe Tyr  
                   130                                  135                                  140  
 Ala Val Met Asp Cys Phe Cys Asp Asn Thr Arg Asn Gln Thr Pro Gln  
                   145                                  150                                  155                                  160  
 Phe Gln Ile Gly Tyr Cys Gln Gln Cys Pro Asp Lys Val Gln Trp Ala  
                                   165                                  170                                  175  
 Ser His Phe Gly Ser Lys Pro Pro Leu Tyr Phe Asn Ala Gly Met Phe  
                   180                                  185                                  190  
 Val Tyr Glu Pro Asn Leu Asp Thr Tyr Arg Asp Leu Leu Gln Thr Val  
                   195                                  200                                  205  
 Gln Leu Thr Lys Pro Thr Ser Phe Ala Glu Gln Asp Phe Leu Asn Met  
                   210                                  215                                  220  
 Tyr Phe Lys Asp Lys Tyr Lys Pro Ile Pro Asn Met Tyr Asn Leu Val  
                   225                                  230                                  235                                  240  
 Leu Ala Met Leu Trp Arg His Pro Glu Asn Val Glu Leu Asp Lys Val  
                                   245                                  250                                  255  
 Gln Val Val His Tyr Cys Ala Ala Gly Ser Lys Pro Trp Arg Phe Thr  
                                   260                                  265                                  270  
 Gly Lys Glu Glu Asn Met Asp Arg Ala Asp Ile Lys Met Leu Val Lys  
                   275                                  280                                  285  
 Lys Trp Trp Asp Ile Tyr Glu Asp Glu Thr Leu Asp Tyr Asn Asn Asn  
                   290                                  295                                  300  
 Ser Val Asn Val Glu Arg Phe Thr Ser Ala Leu Leu Asp Ala Gly Gly  
                   305                                  310                                  315                                  320  
 Phe Gln Phe Val Pro Ala Pro Ser Ala Ala  
                                   325                                  330

<210> 3  
 <211> 1350  
 <212> DNA  
 <213> Glycine max

<400> 3  
 gcacgagaaa caaccaacct cttcagtgat ctttgattag tactaagcta aaccatttct 60  
 tattccctca aaatcaaaac ctttttcttt ctagctatct cccttttcaa atcatgccac 120  
 ctaacatcac caccgttggt gccaatgtca ccaccgagca attaccaag gctcgtggag 180  
 gaagtgggcg tgccttcgtg acctttcttg ctgggaacgg tgattacgta aagggtgtcg 240  
 tgggtttggc caaaggactg agaaaggcca aaagcatgta ccctttgggt gttgctgtgt 300  
 taccagatgt tcctgaagaa catcgtgaga ttctcaaata ccaagggttg attgtcaggg 360  
 agattgaacc tgtgtaccct cctgagaacc agaccagtt cgccatggcc tattatgtca 420  
 tcaattactc caagctacgt atttgggagt tcgtggagta caagaagacg atatacctag 480  
 acggtgacat ccaagtattt ggaaacatag accacttggt tgatctgcct gataattatt 540  
 tctatgcggt gatggattgt ttctgcgaga agacttggag ccacacccct cagttccaga 600  
 ttgggtactg ccaacagtgc cctgataagg ttcaatggcc ctctcacttt ggttccaaac 660  
 ctctctata tttcaatgct ggcattgttg tttatgagcc taatctcgac acctaccgtg 720  
 atcttctcca aactgtccaa ctaccaagc ccacttcttt tgctgagcag gactttctca 780  
 acatgtactt caaggacaag tacaagccaa taccgaacat gtacaacctt gtgctggcca 840  
 tgttgtggcg tcaccctgaa aatgttgaac ttgataaagt tcaagtgggt cattactgtg 900  
 ctgctgggtc taagccttgg aggttctact ggaagggaaga gaacatggat aggggaagata 960  
 tcaagatgct tgtgaagaag tgggtgggaca tatatgaaga tgagacactg gactacaata 1020  
 acaactctgt caacgtggaa cgtttcacat cggcactatt ggatgctggg ggctttcagt 1080  
 ttgtgccagc accttctgct gcctaatatg cttattattt acagctacaa attaatgtta 1140  
 attaacgaca aagtatatgt attgttattt gcttttttct gtttttgggt cttatatatg 1200  
 aaggaacaac gtcctatggt ttaatttggg tgaccttctt gtatacaaaag ccacatgtga 1260  
 tctcatacag cttttgatta ttattaagaa attagaggac cttttattat gagtccttta 1320  
 cttaaaaaaa aaaaaaaaaa aaaaaaaaaa 1350

<210> 4  
 <211> 358  
 <212> PRT  
 <213> Glycine max

<400> 4  
 Ser Leu Ile Ser Thr Lys Leu Asn His Phe Leu Phe Pro Gln Asn Gln  
 1 5 10 15  
 Asn Leu Phe Leu Ser Ser Tyr Phe Pro Phe Gln Ile Met Pro Pro Asn  
 20 25 30  
 Ile Thr Thr Val Val Ala Asn Val Thr Thr Glu Gln Leu Pro Lys Ala  
 35 40 45  
 Arg Gly Gly Ser Gly Arg Ala Phe Val Thr Phe Leu Ala Gly Asn Gly  
 50 55 60  
 Asp Tyr Val Lys Gly Val Val Gly Leu Ala Lys Gly Leu Arg Lys Ala  
 65 70 75 80  
 Lys Ser Met Tyr Pro Leu Val Val Ala Val Leu Pro Asp Val Pro Glu  
 85 90 95  
 Glu His Arg Glu Ile Leu Lys Ser Gln Gly Cys Ile Val Arg Glu Ile  
 100 105 110  
 Glu Pro Val Tyr Pro Pro Glu Asn Gln Thr Gln Phe Ala Met Ala Tyr  
 115 120 125

Tyr Val Ile Asn Tyr Ser Lys Leu Arg Ile Trp Glu Phe Val Glu Tyr  
 130 135 140  
 Lys Lys Thr Ile Tyr Leu Asp Gly Asp Ile Gln Val Phe Gly Asn Ile  
 145 150 155 160  
 Asp His Leu Phe Asp Leu Pro Asp Asn Tyr Phe Tyr Ala Val Met Asp  
 165 170 175  
 Cys Phe Cys Glu Lys Thr Trp Ser His Thr Pro Gln Phe Gln Ile Gly  
 180 185 190  
 Tyr Cys Gln Gln Cys Pro Asp Lys Val Gln Trp Pro Ser His Phe Gly  
 195 200 205  
 Ser Lys Pro Pro Leu Tyr Phe Asn Ala Gly Met Phe Val Tyr Glu Pro  
 210 215 220  
 Asn Leu Asp Thr Tyr Arg Asp Leu Leu Gln Thr Val Gln Leu Thr Lys  
 225 230 235 240  
 Pro Thr Ser Phe Ala Glu Gln Asp Phe Leu Asn Met Tyr Phe Lys Asp  
 245 250 255  
 Lys Tyr Lys Pro Ile Pro Asn Met Tyr Asn Leu Val Leu Ala Met Leu  
 260 265 270  
 Trp Arg His Pro Glu Asn Val Glu Leu Asp Lys Val Gln Val Val His  
 275 280 285  
 Tyr Cys Ala Ala Gly Ser Lys Pro Trp Arg Phe Thr Gly Lys Glu Glu  
 290 295 300  
 Asn Met Asp Arg Glu Asp Ile Lys Met Leu Val Lys Lys Trp Trp Asp  
 305 310 315 320  
 Ile Tyr Glu Asp Glu Thr Leu Asp Tyr Asn Asn Asn Ser Val Asn Val  
 325 330 335  
 Glu Arg Phe Thr Ser Ala Leu Leu Asp Ala Gly Gly Phe Gln Phe Val  
 340 345 350  
 Pro Ala Pro Ser Ala Ala  
 355

<210> 5  
 <211> 341  
 <212> PRT  
 <213> Brassica napus

<400> 5  
 Ala Pro Gly Leu Thr Gln Thr Thr Thr Val Lys Ser Ala Val Thr Ile  
 1 5 10 15  
 Thr Lys Pro Ser Pro Pro Val His Gly Asp Arg Ala Tyr Val Thr Phe  
 20 25 30

Leu Ala Gly Asn Gly Asp Tyr Val Lys Gly Val Val Gly Leu Ala Lys  
                   35                                  40                                  45  
 Gly Leu Arg Lys Val Lys Ser Ala Tyr Pro Leu Val Val Ala Ile Leu  
                   50                                  55                                  60  
 Pro Asp Val Pro Glu Glu His Arg Arg Val Leu Val Glu Gln Gly Cys  
                   65                                  70                                  75                                  80  
 Ile Val Arg Glu Ile Glu Pro Val Tyr Pro Pro Glu Asn Gln Thr Gln  
                                   85                                  90                                  95  
 Phe Ala Met Ala Tyr Tyr Val Ile Asn Tyr Ser Lys Leu Arg Ile Trp  
                   100                                  105                                  110  
 Lys Phe Val Glu Tyr Ser Lys Met Leu Tyr Leu Asp Gly Asp Ile Gln  
                   115                                  120                                  125  
 Val Tyr Glu Asn Ile Asp His Leu Phe Asp Leu Pro Asp Gly Tyr Phe  
                   130                                  135                                  140  
 Tyr Ala Val Met Asp Cys Phe Cys Glu Lys Thr Trp Ser His Thr Pro  
                   145                                  150                                  155                                  160  
 Gln Tyr Lys Ile Gly Tyr Cys Gln Gln Cys Pro Glu Lys Val Gln Trp  
                                   165                                  170                                  175  
 Pro Lys Glu Glu Leu Gly Glu Pro Pro Ser Leu Tyr Phe Asn Ala Gly  
                   180                                  185                                  190  
 Met Phe Val Phe Glu Pro Gly Leu Asp Thr Tyr Glu Asp Leu Leu Arg  
                   195                                  200                                  205  
 Thr Leu Lys Ile Thr Pro Pro Thr Pro Phe Ala Glu Gln Asp Phe Leu  
                   210                                  215                                  220  
 Asn Met Tyr Phe Glu Lys Ile Tyr Lys Pro Ile Pro Leu Val Tyr Asn  
                   225                                  230                                  235                                  240  
 Leu Val Leu Ala Met Leu Trp Arg His Pro Glu Asn Val Glu Leu Asp  
                   245                                  250                                  255  
 Lys Val Lys Val Val His Tyr Cys Ala Ala Gly Ser Lys Pro Trp Arg  
                   260                                  265                                  270  
 Tyr Thr Gly Lys Glu Ala Asn Met Glu Arg Glu Asp Ile Lys Met Leu  
                   275                                  280                                  285  
 Val Asn Lys Trp Trp Asp Ile Tyr Asn Asp Asp Ser Leu Asp Tyr Lys  
                   290                                  295                                  300  
 Lys Ser Val Gly Asp Leu Val Glu Glu Ser Asp Val Val Asn Leu Lys  
                   305                                  310                                  315                                  320  
 Pro Phe Ile Ser Ala Leu Thr Glu Ala Gly Pro Val Lys Tyr Val Thr  
                   325                                  330                                  335  
 Ala Pro Ser Ala Ala  
                   340